Study details
Enrolling now
NVG-291 Trial for Spinal Cord Injury
NervGen Pharma
NCT IDNCT05965700ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
40
Study length
about 2.7 years
Ages
18–75
Locations
1 site in IL
About this study
Researchers are testing NVG-291 in people with spinal cord injuries to see if it improves communication between different parts of the brain. The trial will also assess how safe and well-tolerated NVG-291 is, looking at physical exams, vital signs, and lab tests.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take NVG-291
PhasePhase 1/Phase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Incidences of Treatment Emergent Adverse Events (Safety and Tolerability)
Body systems
Neurology